Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands.
Leukemia. 2012 Jul;26(7):1730-41. doi: 10.1038/leu.2012.30. Epub 2012 Feb 6.
Flow cytometry (FC) is increasingly recognized as an important tool in the diagnosis and prognosis of myelodysplastic syndromes (MDS). However, validation of current assays and agreement upon the techniques are prerequisites for its widespread acceptance and application in clinical practice. Therefore, a working group was initiated (Amsterdam, 2008) to discuss and propose standards for FC in MDS. In 2009 and 2010, representatives from 23, mainly European, institutes participated in the second and third European LeukemiaNet (ELN) MDS workshops. In the present report, minimal requirements to analyze dysplasia are refined. The proposed core markers should enable a categorization of FC results in cytopenic patients as 'normal', 'suggestive of', or 'diagnostic of' MDS. An FC report should include a description of validated FC abnormalities such as aberrant marker expression on myeloid progenitors and, furthermore, dysgranulopoiesis and/or dysmonocytopoiesis, if at least two abnormalities are evidenced. The working group is dedicated to initiate further studies to establish robust diagnostic and prognostic FC panels in MDS. An ultimate goal is to refine and improve diagnosis and prognostic scoring systems. Finally, the working group stresses that FC should be part of an integrated diagnosis rather than a separate technique.
流式细胞术 (FC) 越来越被认为是诊断和预后骨髓增生异常综合征 (MDS) 的重要工具。然而，目前检测方法的验证和技术的一致性是其在临床实践中广泛接受和应用的前提。因此，成立了一个工作组（2008 年，阿姆斯特丹），讨论并提出 MDS 中 FC 的标准。2009 年和 2010 年，来自 23 个主要是欧洲机构的代表参加了第二届和第三届欧洲白血病网（ELN）MDS 研讨会。在本报告中，对分析发育不良的最低要求进行了细化。建议的核心标志物应能够将 FC 结果在血细胞减少患者中分类为“正常”、“提示”或“诊断”为 MDS。FC 报告应包括对验证后的 FC 异常的描述，例如骨髓祖细胞上的异常标记物表达，此外，如果有至少两个异常，则还应包括颗粒形成不良和/或单核细胞形成不良。该工作组致力于开展进一步的研究，以建立 MDS 中稳健的诊断和预后 FC 面板。最终目标是细化和改进诊断和预后评分系统。最后，工作组强调 FC 应该是综合诊断的一部分，而不是单独的技术。
